XML 63 R43.htm IDEA: XBRL DOCUMENT v3.20.4
Quarterly Financial Information (Unaudited) (Tables)
 12 Months Ended
Dec. 31, 2020
Quarterly Financial Information Disclosure [Abstract]  
Schedule of quarterly financial information (unaudited)
The following is a summary of the quarterly results of operations of the Company for the years ended December 31, 2020 and 2019 (unaudited):
 
Quarter EndedQuarter EndedQuarter EndedQuarter Ended
December 31,
2020		September 30,
2020		June 30,
2020		March 31,
2020
Consolidated Statements of Operations:
Revenues:
Revenue under collaborative research and development arrangements$5,003,494 $21,490 $74,102 $71,500 
Revenue under collaborative research and development arrangements from affiliated entities82,774 103,684 95,146 1,172,126 
Other revenue, including from affiliated entities494,313 111,004 97,939 83,648 
Total revenues5,580,581 236,178 267,187 1,327,274 
Operating Expenses:
Research and development26,302,561 26,455,112 22,376,575 19,111,188 
General and administrative8,617,458 10,110,506 11,071,510 7,448,354 
Total operating expenses34,920,019 36,565,618 33,448,085 26,559,542 
Loss from operations(29,339,438)(36,329,440)(33,180,898)(25,232,268)
Interest income931,168 896,710 1,067,399 416,569 
Interest expense(1,068,008)(1,984,046)(2,846,641)(2,803,755)
Change in fair value of derivative liability— 35,306,000 (97,755,000)(13,221,977)
Gain (loss) on investment in affiliated entities306,317 26,951,898 (3,883,176)13,181,619 
Net unrealized gain on available-for-sale equity securities1,070,975 1,315,980 4,358,634 (5,050,092)
Other income (expense), net9,350 (136,644)(152,102)(425,500)
Gain on deconsolidation of Geneos— — 4,121,075 — 
Loss on extinguishment of convertible bonds— (8,177,043)— — 
Gain on extinguishment of convertible senior notes5,674,435 3,087,595 — — 
Net income (loss) before income tax benefit and share in net loss of Geneos$(22,415,201)$20,931,010 $(128,270,709)$(33,135,404)
Share in net loss of Geneos(1,923,179)(1,759,674)(901,757)— 
Net income (loss)$(24,338,380)$19,171,336 $(129,172,466)$(33,135,404)
Net loss attributable to non-controlling interest— — 469,407 594,350 
Net income (loss) attributable to Inovio Pharmaceuticals, Inc.$(24,338,380)$19,171,336 $(128,703,059)$(32,541,054)
Net income (loss) per share
Basic$(0.14)$0.12 $(0.83)$(0.26)
Diluted$(0.14)$0.11 $(0.83)$(0.26)


 
Quarter EndedQuarter EndedQuarter EndedQuarter Ended
December 31,
2019		September 30,
2019		June 30,
2019		March 31,
2019
Consolidated Statements of Operations:
Revenues:
Revenue under collaborative research and development arrangements$184,523 $617,427 $64,283 $2,770,712 
Revenue under collaborative research and development arrangements from affiliated entities55,665 53,014 71,390 55,579 
Other revenue, including from affiliated entities39,300 196,422 — 3,614 
Total revenues279,488 866,863 135,673 2,829,905 
Operating Expenses:
Research and development22,003,955 19,137,209 22,486,266 24,389,888 
General and administrative8,696,586 5,681,441 5,850,101 6,975,029 
Total operating expenses30,700,541 24,818,650 28,336,367 31,364,917 
Loss from operations(30,421,053)(23,951,787)(28,200,694)(28,535,012)
Interest income587,679 637,438 755,330 625,535 
Interest expense(2,668,837)(2,428,671)(2,194,783)(656,248)
Change in fair value of derivative liability(4,315,105)2,551,453 — — 
Loss from investment in affiliated entities(1,681,401)(485,841)(173,212)(750,103)
Other income (expense), net263,571 140,956 127,512 (35,839)
Net loss before income tax benefit(38,235,146)(23,536,452)(29,685,847)(29,351,667)
Income tax benefit87,764 — 106,771 62,800 
Net loss(38,147,382)(23,536,452)(29,579,076)(29,288,867)
Net loss attributable to non-controlling interest485,344 445,759 191,850 69,605 
Net loss attributable to Inovio Pharmaceuticals, Inc.$(37,662,038)$(23,090,693)$(29,387,226)$(29,219,262)
Net loss per share
          Basic$(0.38)$(0.23)$(0.30)$(0.30)
          Diluted$(0.38)$(0.25)$(0.30)$(0.30)